Latest From Oragenics Inc.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Agilis Biotherapeutics has entered into a deal with synthetic biology firm Intrexon to develop DNA-based therapeutics for the rare genetic disease, Friedreich's ataxia.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October through November 2013.
A new life sciences hedge fund operated by two former associates of activist investor Carl Icahn is challenging Otsuka’s takeover of cancer drug developer Astex. Also, Johnson & Johnson’s London Innovation Center announced four alliances, Celgene took another option on one of its investments and Takeda teamed up with New York research institutions to form a new discovery institute.
- OTC, Consumer
- Therapeutic Areas
- Infectious & Viral Diseases
- ONI BioPharma Inc.
- North America
- Parent & Subsidiaries
- Oragenics Inc.
- Senior Management
Alan Joslyn, PhD, Pres. & CEO
Michael Sullivan, CFO
Martin Handfield, PhD, SVP, Discovery Rsch.
- Contact Info
Phone: (813) 286-7900
4902 Eisenhower Blvd., Ste. 125
Tampa, FL 33634
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.